Ricerca
Cheratocongiuntivite primaverile (vernal)
Vernal keratoconjunctivitis
GRUPPO DI STUDIO SULLA VERNAL
Coordinamento: Rosario Cavallo, Pediatra di famiglia, Salice Salentino, Lecce; Fulvio Parentin, SC Oculistica e Strabologia,
IRCCS Materno-Infantile “Burlo Garofolo”, Trieste
Pediatri di famiglia partecipanti: EMILIA ROMAGNA: Caracalla M., Gorini S., Panza C.; FRIULI VENEZIA GIULIA: Lizzi D.,
Ulliana A.; LAZIO: Reali L.; LOMBARDIA: Di Francesco C., Narducci M., Zanetto F.; PUGLIA: Altavilla T., Bonavota L., Casile C., Cavallo R., Chiriacò G., Cimino S., Dell'Edera L., Donno A., Giuliano B., Guacci P., Innocente M., Lisi V., Lombardo D.,
Peschiulli G., Petrone D., Rella F., Santoro A., Simeone G., Truppa G.; SICILIA: Amoruso B., Primavera G., Spataro A.;
TOSCANA: Castelli S., Neri P.; UMBRIA: Bianchi S.; VENETO: Comacchio S., Fusco F., Matticchio G., Pasinato A., Sambugaro D.
Novembre 2013 - pagg. 578 -584
Abstract
Background - Vernal keratoconjunctivitis (VKC) is a chronic-recurrent type of conjunctivitis
that may negatively affect the quality of life of patients. It is a rare disease that mainly
affects the paediatric age group and tends to resolve in the pubertal age. VKC is usually
disregarded both by paediatricians and ophthalmologists.
Objectives - To verify the prevalence of VKC and its management modalities in a reference population of 35,000 children and adolescents aged < 16 years by a study group of 39 Italian family paediatricians.
Methods - It is an observational study. The study group received a diagnostic protocol on VKC and other forms of conjunctivitis. During the study season the group of paediatricians highlighted all the cases of Vernal among their patients. The paediatricians specified whether the VKC diagnosis was already known or was made during the season, whether there was a reacutization during the study season or a remission and the administered therapy.
Results - 94 VKC cases were observed (34 new diagnoses and 60 cases that had been identified in the previous years), with a prevalence of 1 case/377 (26.5:10,000 patients < 16 years). The incidence of new cases / year in the assisted population is 1 case / 1,042 assisted children (9.6/10,000 children < 16 years). 59 children were treated with cortisone eye drops, 13 were treated both with cortisone and cyclosporine eye drops and 22 with cyclosporine eye drops.
Conclusions - VKC is probably a much more frequent disease than it is generally thought of. Family paediatricians can make an efficacious praecox diagnosis and, with the help of the ophthalmologists, manage and treat this pathology that is often disregarded.
Objectives - To verify the prevalence of VKC and its management modalities in a reference population of 35,000 children and adolescents aged < 16 years by a study group of 39 Italian family paediatricians.
Methods - It is an observational study. The study group received a diagnostic protocol on VKC and other forms of conjunctivitis. During the study season the group of paediatricians highlighted all the cases of Vernal among their patients. The paediatricians specified whether the VKC diagnosis was already known or was made during the season, whether there was a reacutization during the study season or a remission and the administered therapy.
Results - 94 VKC cases were observed (34 new diagnoses and 60 cases that had been identified in the previous years), with a prevalence of 1 case/377 (26.5:10,000 patients < 16 years). The incidence of new cases / year in the assisted population is 1 case / 1,042 assisted children (9.6/10,000 children < 16 years). 59 children were treated with cortisone eye drops, 13 were treated both with cortisone and cyclosporine eye drops and 22 with cyclosporine eye drops.
Conclusions - VKC is probably a much more frequent disease than it is generally thought of. Family paediatricians can make an efficacious praecox diagnosis and, with the help of the ophthalmologists, manage and treat this pathology that is often disregarded.
Classificazione MeSH
Bibliografia
1. Leonardi A. Vernal keratoconjunctivitis:
pathogenesis and treatment. Prog Retin Eye
Res 2002;21:319-39.
2. Lambiase A, Minchiotti S, Leonardi A, et al. Prospective, multicenter demographic and
epidemiological study on vernal keratoconjunctivitis:
a glimpse of ocular surface in Italian
population. Ophthalmic Epidemiol 2009;
16:38-41.
3. Leonardi A, Busca F, Motterle L, et al. Case
series of 406 vernal keratoconjunctivitis patients:
a demographic and epidemiological
study. Acta Ophthalmol Scand 2006;84:406-10.
4. Pucci N, Pingitore G, Arrigoni S, et al.;
Commissione Rinocongiuntivite della SIAIP.
Diagnosi differenziale delle congiuntiviti allergiche.
Rivista di Allergologia e Immunologia
Pediatrica 2010;01:11-8.
5. Pucci N, Azzari C, Vierucci A. La cheratocongiuntivite
vernal. Rivista di Immunologia
e Allergologia Pediatrica 2007;2:37-44.
6. Bremond-Gignac D, Donadieu J, Leonardi
A, et al. Prevalence of vernal keratoconjunctivitis:
a rare disease? Br J Ophthalmol 2008;
92:1097-102.
7. European Medicines Agency. Public summary
of opinion on orphan designation. Committee
for Orphan Medicinal Products, 12 October
2010, EMA/COMP/1610/2003 Rev. 2,
pag. 1-4.
8. Bielory L. Allergic and immunologic disorders
of the eye. Part II: Ocular allergy. J Allergy
Clin Immunol 2000;106:1019-32.
9. Montan PG, Ekström K, Hedlin G, van
Hage-Hamsten M, Hjern A, Herrmann B. Vernal
keratoconjunctivitis in a Stockholm ophthalmic
centre-epidemiological, functional,
and immunologic investigations. Acta Ophthalmol
Scand 1999;77:559-63.
10. Bielory L, Friedlaender MH. Allergic conjunctivitis.
Immunol Allergy Clin North Am
2008;28:43-58.
11. Nucci P. Tre problemi oculari da ben gestire
nel prossimo decennio. Medico e Bambino
2010;29:515-8.
12. Bonini S, Bonini S, Lambiase A, et al. Vernal
keratoconjunctivitis revisited: a case series
of 195 patients with long-term follow up. Ophtalmology
2000;107:1157-63.
13. De Smedt S, Wildner G, Kestelyn P. Vernal
keratoconjunctivitis: an update. Br J Ophthalmol
2013;97(1):9-14.
14. Bielory BP, O’Brien TP, Bielory L. Management
of seasonal allergic conjunctivitis:
guide to therapy. Acta Ophthalmol 2012;90:
399-407.
15. Oner V, Türkcü FM, Ta M, Alaku MF, I -
can Y. Topical loteprednol etabonate 0.5% for
treatment of vernal keratoconjunctivitis: efficacy
and safety. Jpn J Ophthalmol 2012;56:
312-8.
16. Comstock TL, Paterno MR, Bateman KM,
Decory HH, Gearinger M. Safety and tolerability
of loteprednol etabonate 0.5% and tobramycin
0.3% ophthalmic suspension in pediatric
subjects. Paediatr Drugs 2012;14:119-
30.
Corrispondenza: rcavallo58@gmail.com